Raman spectroscopy is emerging as a powerful tool in virology, offering rapid, label-free insight into viruses and host responses – but translating that promise into real-world diagnostics remains a work in progress. A new review surveys how Raman and its enhanced variants are being deployed against pandemic-prone viruses, from influenza and SARS-CoV-2 to Ebola and dengue, revealing both striking advances and persistent gaps.
At its core, Raman spectroscopy provides molecular “fingerprinting” of biological samples without the need for labels or destructive processing. As the authors note, “Raman spectroscopy, with its ability to provide molecular fingerprinting of biological samples, has recently emerged as a powerful technique in virology.” Enhanced approaches – such as SERS, TERS, and CARS – push sensitivity and resolution further, enabling detection of viral particles, biochemical changes, and virus-host interactions in near real time.
Across the literature, Raman-based methods have demonstrated impressive performance: rapid influenza detection in minutes, SARS-CoV-2 identification in saliva and swabs with high accuracy, and even multiplexed detection of viruses in complex samples. Yet the review also highlights a striking imbalance. Research is heavily concentrated on accessible, high-impact viruses, while high-risk pathogens like Lassa or Marburg remain underexplored due to biosafety constraints and limited access.
Despite clear progress, technical barriers remain. Weak signal intensity, fluorescence interference, and lack of standardization continue to limit reproducibility and clinical translation. As the authors emphasize, “these challenges include weak intrinsic signal intensity, fluorescence interference, limited depth penetration… and barriers to clinical translation.” Regulatory hurdles and the complexity of integrating AI-driven analysis add further friction.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
